Adverse events: need for reoperation/ reimplantation · adults with chronic pain
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events: bronchospasm/treatment discontinued · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: bronchospasm/treatment discontinued compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Infants with Probably Related Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers
It is very uncertain whether an extended NVP plus ZDV regimen administered to infants for 14 weeks changes infants with Probably Related Severe Adverse Events compared with sdNVP plus ZDV (1 week) (very low certainty).
1 finding from 1 review
Infants with Probably Related Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers
It is very uncertain whether an extended NVP plus ZDV dual regimen administered to infants for 14… changes infants with Probably Related Severe Adverse Events compared with an extended NVP regimen administered to infants (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Four of the participants withdrew from the study by Kimos et al 2007 due to adverse effects, but neither the type of adverse effect nor the trial group was specified.
1 study · 44 participants
GRADE not reported
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Serious adverse events or complications of treatment
It is very uncertain whether shock wave lithotripsy changes serious adverse events or complications of treatment compared with ureteroscopy with holmium laser or pneumatic lithotripsy (very low certainty).
1 finding from 1 review
Serious adverse events or complications of treatment
Shock wave lithotripsy may leads to lower serious adverse events or complications of treatment compared with mini‐percutaneous nephrolithotripsy (low certainty).
1 finding from 1 review
Serious adverse events or complications of treatment
It is very uncertain whether shock wave lithotripsy changes serious adverse events or complications of treatment compared with dissolution therapy (very low certainty).
1 finding from 1 review
Serious adverse events or complications of treatment
1 finding from 1 review
Serious adverse events or complications of treatment
1 finding from 1 review
Serious adverse events or complications of treatments
It is very uncertain whether percutaneous nephrolithotripsy changes serious adverse events or complications of treatments compared with tubeless percutaneous nephrolithotripsy (very low certainty).
1 finding from 1 review
Infants with Probably Related Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers
It is very uncertain whether an extended NVP regimen administered to infants for 14 weeks changes infants with Probably Related Severe Adverse Events11 compared with sdNVP plus ZDV (1week) (very low certainty).
1 finding from 1 review
Adverse effects: suicidal thoughts (events) · people in the prodromal stage of psychosis
It is very uncertain whether group A: amino acids changes adverse effects: suicidal thoughts Short‐term (events) compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events ‐ Haemodilution versus control. · patients with liver resection.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · participants with tophi in gout
Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
1 finding from 1 review